TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21968664

Group type: EXPERIMENTAL
Intervention: NAFT‐2%
Number of subjects: 334

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 334
Study: 19032529

Group type: EXPERIMENTAL
Intervention: MI-consistent behaviours
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: MI-inconsistent behaviours
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Other counsellor behaviours
Number of subjects: 97
Study: 21038021

Group type: EXPERIMENTAL
Intervention: Medical therapy (Dexarhinaspray duo and nasal douche)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Surgical therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 90
Study: 15608312

Group type: EXPERIMENTAL
Intervention: Roentgen irradiation (20 Gy over 2 weeks)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sham irradiation (control group)
Number of subjects: 6
Study: 12398148

Group type: EXPERIMENTAL
Intervention: Standard preparation with chlorhexidine gluconate home scrubs and preoperative povidone‐iodine
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard preparation plus preoperative preparation with 70% alcohol
Number of subjects: 49
Study: 9730356

Group type: EXPERIMENTAL
Intervention: Social Skills Training (SST)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Didactic Training (DT)
Number of subjects: 307

Group type: COMPARATOR
Intervention: No Training (NT)
Number of subjects: 307
Study: 7916020

Group type: EXPERIMENTAL
Intervention: 0.05% levocabastine
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo vehicle
Number of subjects: 47
Study: 2610502

Group type: EXPERIMENTAL
Intervention: Aluminum magnesium hydroxide (10 ml per dose for 10 doses)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pirenzepine (50 mg per dose for 4 doses)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg per dose for 3 doses)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Amoxicillin (1,000 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cephalexin (1,000 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid (625 mg)
Number of subjects: 10
Study: 12449294

Group type: EXPERIMENTAL
Intervention: Three servings of yogurt added to daily diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Three servings of a nutrition‐poor snack (control)
Number of subjects: 0
Study: 29208626

Group type: EXPERIMENTAL
Intervention: Niacin (1500 or 2000 mg)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 352
Study: 27903262

Group type: EXPERIMENTAL
Intervention: Test mouthwash (0.25 mg/ml green tea and 7.82 mg/ml Salvadora persica L.)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 14

Group type: COMPARATOR
Intervention: 0.12% chlorhexidine (control)
Number of subjects: 14
Study: 25876344

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Dyne-35 (western medication)
Number of subjects: 65
Study: 22578380

Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) 50mg prior to CBT sessions
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo prior to CBT sessions
Number of subjects: 44
Study: 20472113

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive (OC)
Number of subjects: 30
Study: 18332449

Group type: EXPERIMENTAL
Intervention: Icodextrin 1000 mL
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Icodextrin 1500 mL
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Icodextrin 2500 mL
Number of subjects: 13
Study: 15989115

Group type: EXPERIMENTAL
Intervention: Head-up tilt test (HUT)
Number of subjects: 61
Study: 12914790

Group type: EXPERIMENTAL
Intervention: Non-dialysed (ND)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Haemodialysed (HD)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis (PD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ESRD patients
Number of subjects: 60
Study: 10589824

Group type: EXPERIMENTAL
Intervention: High nausea group (9 patients)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low nausea group (11 patients)
Number of subjects: 20
Study: 8588384

Group type: EXPERIMENTAL
Intervention: GHRH administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 1835318

Group type: EXPERIMENTAL
Intervention: Rectus sheath and mesosalpinx blocks (group B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standardised general anaesthetic and rectus sheath block (group A)
Number of subjects: 30
Study: 7021447

Group type: EXPERIMENTAL
Intervention: Mianserin (60 mg daily)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Chlorimipramine (150 mg daily)
Number of subjects: 145
Study: 30587610

Group type: EXPERIMENTAL
Intervention: Moisturizing cream containing lipopolysaccharide (LPSp)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo moisturizing cream
Number of subjects: 0
Study: 29064651

Group type: EXPERIMENTAL
Intervention: Solifenacin (SS)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Percutaneous tibial nerve stimulation (PTNS)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Combination of PTNS + SS
Number of subjects: 105
Study: 27105761

Group type: EXPERIMENTAL
Intervention: KNN51 (K-nearest neighbor classifier 51)
Number of subjects: 199

Group type: COMPARATOR
Intervention: RF15 (15-gene cancer recurrence signature)
Number of subjects: 199

Group type: COMPARATOR
Intervention: LN20 (20-gene lymph node signature)
Number of subjects: 199
Study: 25491041

Group type: EXPERIMENTAL
Intervention: Supportive supervision and community mobilization
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Community mobilization alone
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combined interventions arm
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Community mobilization arm
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combined interventions arm (women)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control arm (women)
Number of subjects: 120
Study: 22431052

Group type: EXPERIMENTAL
Intervention: Health education pathway
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional health education
Number of subjects: 100
Study: 20060499

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 1474
Study: 17680205

Group type: EXPERIMENTAL
Intervention: Saline infiltration of the scalp
Number of subjects: 44

Group type: COMPARATOR
Intervention: Lidocaine infiltration of the scalp
Number of subjects: 44
Study: 16080808

Group type: EXPERIMENTAL
Intervention: ACE inhibitor-perindopril (+ diuretic-indapamide)
Number of subjects: 1520
Study: 12061605

Group type: EXPERIMENTAL
Intervention: Slow tempo condition
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Fast tempo condition
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: No tempo condition
Number of subjects: 240
Study: 11136842

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (ERT)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Raloxifene (higher dose)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Raloxifene (lower dose)
Number of subjects: 168
Study: 9848309

Group type: EXPERIMENTAL
Intervention: Hypoosmotic swelling test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Water test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eosin-Y staining
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: None of the membrane integrity tests
Number of subjects: 0
Study: 7978777

Group type: EXPERIMENTAL
Intervention: Generalized anxiety disorder patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 2542549

Group type: EXPERIMENTAL
Intervention: ANP infusion at 0.1 microgram/min with enalaprilat (5 micrograms/min)
Number of subjects: 6

Group type: COMPARATOR
Intervention: ANP infusion at 0.1 microgram/min with placebo (saline)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: First ANP infusion (0.1 microgram/min) before placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: First ANP infusion (0.1 microgram/min) before enalaprilat
Number of subjects: 6
Study: 796940

Group type: EXPERIMENTAL
Intervention: Ketoprofen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phenylbutazone
Number of subjects: 0
Study: 31498264

Group type: EXPERIMENTAL
Intervention: Intraarticular TXA only (simultaneous TKA)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Combined IV and intraarticular TXA (simultaneous TKA)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Intraarticular TXA only (staged TKA)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Combined IV and intraarticular TXA (staged TKA)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Intraarticular TXA only and Combined IV and intraarticular TXA
Number of subjects: 310
Study: 30573004

Group type: EXPERIMENTAL
Intervention: 100 mg of prednisolone
Number of subjects: 14
Study: 27885448

Group type: EXPERIMENTAL
Intervention: Disease-modifying therapies (DMTs): IFNB1-a SC, IFNB1-b, GA
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Disease-modifying therapies (DMTs)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: IFNB and GA
Number of subjects: 161
Study: 25968495

Group type: EXPERIMENTAL
Intervention: Ivabradine with carvedilol
Number of subjects: 5960

Group type: EXPERIMENTAL
Intervention: Ivabradine with bisoprolol
Number of subjects: 5960

Group type: EXPERIMENTAL
Intervention: Ivabradine with metoprolol
Number of subjects: 5960

Group type: EXPERIMENTAL
Intervention: Ivabradine with nebivolol
Number of subjects: 5960

Group type: COMPARATOR
Intervention: Carvedilol with placebo
Number of subjects: 5960
Study: 23651816

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of bone marrow mesenchymal stem cells (BMSCs); n=21
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard medical treatment; n=22
Number of subjects: 43
Study: 21764225

Group type: EXPERIMENTAL
Intervention: Without peritonisation
Number of subjects: 252

Group type: COMPARATOR
Intervention: With peritonisation
Number of subjects: 252
Study: 19290426

Group type: EXPERIMENTAL
Intervention: Glass fiber‐reinforced post core
Number of subjects: 100

Group type: COMPARATOR
Intervention: Metal cast post core
Number of subjects: 100
Study: 16945045

Group type: EXPERIMENTAL
Intervention: TrimSpa (ephedra 15 mg and caffeine 60 mg, 3 times/day for 7 days)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (matching placebo, 3 times/day for 7 days)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: TrimSpa
Number of subjects: 13
Study: 14628097

Group type: EXPERIMENTAL
Intervention: [(11)C]choline PET
Number of subjects: 19
Study: 11406335

Group type: EXPERIMENTAL
Intervention: 100 mg peroral ketoprofen
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 50 mg peroral ketoprofen
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 100 mg topical 2.5% ketoprofen gel
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 50 mg topical ketoprofen gel
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 6
Study: 9246958

Group type: EXPERIMENTAL
Intervention: pH
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: DAO
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: IGFBP1
Number of subjects: 100
Study: 7920940

Group type: EXPERIMENTAL
Intervention: Mifepristone (RU486) 600 mg
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (Placebo)
Number of subjects: 46
Study: 3521444

Group type: EXPERIMENTAL
Intervention: Cholestyramine 2 g twice daily for 3 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30977581

Group type: EXPERIMENTAL
Intervention: Physiotherapists' self-audit of performance
Number of subjects: 8

Group type: COMPARATOR
Intervention: Training facilitator's audit of performance
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Person-centred practice principles
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Behaviour change techniques
Number of subjects: 8
Study: 30264456

Group type: EXPERIMENTAL
Intervention: QLV-based implant strategy
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 250
Study: 25581159

Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg) 100 U/mL, subcutaneously, at doses of 0.4-0.8 U/kg for 6-12 days
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg)
Number of subjects: 195
Study: 25194583

Group type: EXPERIMENTAL
Intervention: Behavioral sleep problems
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Co-occurring internalizing and externalizing comorbidities
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Greater ADHD symptom severity
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Poorer caregiver mental health
Number of subjects: 195
Study: 22796997

Group type: EXPERIMENTAL
Intervention: H60
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: H90
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: S60
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: S90
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: All protocols
Number of subjects: 6
Study: 20609719

Group type: EXPERIMENTAL
Intervention: Totally extraperitoneal (TEP) procedure
Number of subjects: 64

Group type: COMPARATOR
Intervention: Stoppa procedure
Number of subjects: 64
Study: 17671280

Group type: EXPERIMENTAL
Intervention: Citalopram treatment
Number of subjects: 1816

Group type: EXPERIMENTAL
Intervention: GRIK4 gene marker (rs1954787)
Number of subjects: 1816

Group type: EXPERIMENTAL
Intervention: HTR2A gene marker
Number of subjects: 1816
Study: 16224673

Group type: EXPERIMENTAL
Intervention: Preoperative Halo-traction
Number of subjects: 25

Group type: COMPARATOR
Intervention: Direct operative correction and instrumentation (no Halo-traction)
Number of subjects: 25
Study: 14605997

Group type: COMPARATOR
Intervention: Bolus rGLP-1 injections at 1.5 nmol/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Continuous rGLP-1 infusion at up to 4.5 pmol/kg/min
Number of subjects: 40

Group type: COMPARATOR
Intervention: Continuous rGLP-1 infusion in SU cohort
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: rGLP-1 infusions
Number of subjects: 40
Study: 10584647

Group type: EXPERIMENTAL
Intervention: Twice-daily heparin flushes with once-weekly urokinase instillation (group B, n = 53)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Twice-daily heparin flushes (group A, n = 52)
Number of subjects: 105
Study: 8911112

Group type: EXPERIMENTAL
Intervention: Dolasetron mesilate 25 mg
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Dolasetron mesilate 50 mg
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Dolasetron mesilate 100 mg
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Dolasetron mesilate 200 mg
Number of subjects: 399

Group type: COMPARATOR
Intervention: Ondansetron (8 mg x 3 or 8 mg x 4)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Dolasetron mesilate and Ondansetron
Number of subjects: 399
Study: 1868444

Group type: EXPERIMENTAL
Intervention: Acarbose (BAY g 5421)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6135820

Group type: EXPERIMENTAL
Intervention: Metipranolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Timolol (Control)
Number of subjects: 0
Study: 3010510

Group type: EXPERIMENTAL
Intervention: CMV hyperimmune globulin
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control immune globulin
Number of subjects: 49
Study: 31179773

Group type: EXPERIMENTAL
Intervention: Oral mucoadhesive film containing chitosan
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study: 29584492

Group type: EXPERIMENTAL
Intervention: Bicycle helmets tested at 3.4 m/s
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bicycle helmets tested at 6.2 m/s
Number of subjects: 10
Study: 27912735

Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb measles vaccine at 4.5 and 9 months (group A)
Number of subjects: 6648

Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb measles vaccine at 4.5 months (group A)
Number of subjects: 6648

Group type: COMPARATOR
Intervention: No vaccine at 4.5 months and Edmonston-Zagreb measles vaccine at 9 months (group B)
Number of subjects: 6648

Group type: COMPARATOR
Intervention: No vaccine at 4.5 months and Schwarz measles vaccine at 9 months (group C)
Number of subjects: 6648
Study: 24636340

Group type: EXPERIMENTAL
Intervention: Before-contouring era (BC)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Post-contouring era (PC)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Internal mammary chain (IMC) treated
Number of subjects: 140

Group type: COMPARATOR
Intervention: Conservation vs Mastectomy
Number of subjects: 140

Group type: COMPARATOR
Intervention: Boost vs No Boost
Number of subjects: 140
Study: 24040472

Group type: EXPERIMENTAL
Intervention: Negatively-charged aerosol therapy (2 hours per time, twice a day)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Normal, routine treatment
Number of subjects: 140
Study: 20942277

Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion therapy of excitation‐focus transfer
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine medications
Number of subjects: 80
Study: 18560130

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 1826

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1826
Study: 16809801

Group type: EXPERIMENTAL
Intervention: Single-dose ritonavir 100 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Single-dose lopinavir/ritonavir 400/100 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Steady-state lopinavir/ritonavir 400/100 mg twice daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (fexofenadine 120 mg alone)
Number of subjects: 16
Study: 11501455

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) biopsy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Axillary dissection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SLN biopsy followed by backup axillary dissection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SLN biopsy
Number of subjects: 0
Study: 9931866

Group type: EXPERIMENTAL
Intervention: Minimally invasive and endoscopic saphenous vein harvesting
Number of subjects: 55

Group type: COMPARATOR
Intervention: Conventional saphenous vein harvesting
Number of subjects: 55
Study: 7983661

Group type: EXPERIMENTAL
Intervention: 20 mg tenoxicam
Number of subjects: 307

Group type: COMPARATOR
Intervention: 500-1000 mg naproxen
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Both tenoxicam and naproxen
Number of subjects: 307
Study: 2691478

Group type: EXPERIMENTAL
Intervention: Cefotaxime 100 mg/kg/d in four divided iv doses for 14 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Amoxycillin/clavulanate 100 mg/kg/d in four divided iv doses for seven days, then oral 50 mg/kg/d for seven days
Number of subjects: 20
Study: 51284

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Inhaled betamethasone valerate
Number of subjects: 75

Group type: COMPARATOR
Intervention: Oral prednisone
Number of subjects: 75
Study: 31838180

Group type: EXPERIMENTAL
Intervention: Lindioil ointment
Number of subjects: 48

Group type: COMPARATOR
Intervention: Vehicle ointment
Number of subjects: 48
Study: 30018165

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention supporting activities to improve penicillin delivery, aligned with the chronic care model, with continuous quality-improvement feedback on adherence.
Number of subjects: 304

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 304
Study: 27333534

Group type: EXPERIMENTAL
Intervention: Dry needling with 0.25 mm diameter needles (group A)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Dry needling with 0.5 mm diameter needles (group B)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Dry needling with 0.9 mm diameter needles (group C)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Dry needling with varying needle diameters (0.25, 0.5, and 0.9 mm)
Number of subjects: 48
Study: 25055716

Group type: EXPERIMENTAL
Intervention: Latrine cleaning intervention
Number of subjects: 17564

Group type: EXPERIMENTAL
Intervention: Handwashing with soap
Number of subjects: 17564

Group type: COMPARATOR
Intervention: Control group (no latrine cleaning intervention)
Number of subjects: 17564
Study: 23327021

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (0.2 mg/kg)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Oral acetaminophen codeine (20 mg/kg)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo (oral and intravenous)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: All groups (dexamethasone, acetaminophen codeine, placebo)
Number of subjects: 105
Study: 20478320

Group type: EXPERIMENTAL
Intervention: Cognitive task of subtracting backwards by seven
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive task of generating words of the same first letter
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low visuospatial processing load (eyes closed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normal visuospatial processing load (eyes open)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High visuospatial processing load (eyes open, sway-referenced surround)
Number of subjects: 0
Study: 18760982

Group type: EXPERIMENTAL
Intervention: Experimental group (self-monitoring and forming specific action plans for walking)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (self-monitoring daily pedometer-determined step count)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 75
Study: 16320096

Group type: EXPERIMENTAL
Intervention: Analogue tasks (empty time and time listening to an audiobook)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Sleep setting (nocturnal sleep and awake times)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Night-to-night wake time variability
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Psychological adjustment
Number of subjects: 148